202 related articles for article (PubMed ID: 34636747)
21. MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.
Monk BJ; Grisham RN; Banerjee S; Kalbacher E; Mirza MR; Romero I; Vuylsteke P; Coleman RL; Hilpert F; Oza AM; Westermann A; Oehler MK; Pignata S; Aghajanian C; Colombo N; Drill E; Cibula D; Moore KN; Christy-Bittel J; Del Campo JM; Berger R; Marth C; Sehouli J; O'Malley DM; Churruca C; Boyd AP; Kristensen G; Clamp A; Ray-Coquard I; Vergote I
J Clin Oncol; 2020 Nov; 38(32):3753-3762. PubMed ID: 32822286
[TBL] [Abstract][Full Text] [Related]
22. Somatic Genomic and Transcriptomic Characterization of Primary Ovarian Serous Borderline Tumors and Low-Grade Serous Carcinomas.
Stružinská I; Hájková N; Hojný J; Krkavcová E; Michálková R; Bui QH; Matěj R; Laco J; Drozenová J; Fabian P; Škapa P; Špůrková Z; Cibula D; Frühauf F; Jirásek T; Zima T; Méhes G; Kendall Bártů M; Němejcová K; Dundr P
J Mol Diagn; 2024 Apr; 26(4):257-266. PubMed ID: 38280423
[TBL] [Abstract][Full Text] [Related]
23. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube.
Noguera IR; Sun CC; Broaddus RR; Branham D; Levenback CF; Ramirez PT; Sood AK; Coleman RL; Gershenson DM
Gynecol Oncol; 2012 Jun; 125(3):640-5. PubMed ID: 22387451
[TBL] [Abstract][Full Text] [Related]
24. Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma.
Llaurado Fernandez M; Dawson A; Kim H; Lam N; Russell H; Bruce M; Bittner M; Hoenisch J; Scott SA; Talhouk A; Chiu D; Provencher D; Nourmoussavi M; DiMattia G; Lee CH; Gilks CB; Köbel M; Carey MS
Gynecol Oncol; 2020 Apr; 157(1):12-20. PubMed ID: 31954537
[TBL] [Abstract][Full Text] [Related]
25. Low-Grade Serous Carcinoma of the Ovary: The Current Status.
Babaier A; Mal H; Alselwi W; Ghatage P
Diagnostics (Basel); 2022 Feb; 12(2):. PubMed ID: 35204549
[TBL] [Abstract][Full Text] [Related]
26. Low-grade serous carcinoma: new concepts and emerging therapies.
Romero I; Sun CC; Wong KK; Bast RC; Gershenson DM
Gynecol Oncol; 2013 Sep; 130(3):660-6. PubMed ID: 23707670
[TBL] [Abstract][Full Text] [Related]
27. Treatment of Recurrent Low-grade Serous Ovarian Cancer With MEK Inhibitors: A Systematic Review.
Kulkarni A; Cooke C; Fazelzad R; Fung-Kee-Fung M; May T; Zigras T
Am J Clin Oncol; 2024 Jan; 47(1):11-16. PubMed ID: 37823720
[TBL] [Abstract][Full Text] [Related]
28. Differences of chemoresistance assay between invasive micropapillary/low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma.
Santillan A; Kim YW; Zahurak ML; Gardner GJ; Giuntoli RL; Shih IM; Bristow RE
Int J Gynecol Cancer; 2007; 17(3):601-6. PubMed ID: 17504374
[TBL] [Abstract][Full Text] [Related]
29. Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability.
Shrestha R; Llaurado Fernandez M; Dawson A; Hoenisch J; Volik S; Lin YY; Anderson S; Kim H; Haegert AM; Colborne S; Wong NKY; McConeghy B; Bell RH; Brahmbhatt S; Lee CH; DiMattia GE; Le Bihan S; Morin GB; Collins CC; Carey MS
Cancer Res; 2021 Apr; 81(7):1681-1694. PubMed ID: 33441310
[TBL] [Abstract][Full Text] [Related]
30. Ovarian Low-grade Serous Carcinoma: A Clinicopathologic Study of 33 Cases With Primary Surgery Performed at a Single Institution.
Okoye E; Euscher ED; Malpica A
Am J Surg Pathol; 2016 May; 40(5):627-35. PubMed ID: 26900814
[TBL] [Abstract][Full Text] [Related]
31. Gene expression profiles of ovarian low-grade serous carcinoma resemble those of fallopian tube epithelium.
Qiu C; Lu N; Wang X; Zhang Q; Yuan C; Yan S; Dongol S; Li Y; Sun X; Sun C; Zhang Z; Zheng W; Kong B
Gynecol Oncol; 2017 Dec; 147(3):634-641. PubMed ID: 28965696
[TBL] [Abstract][Full Text] [Related]
32. Ki67 expression as a predictor of chemotherapy outcome in low-grade serous ovarian cancer.
Grabowski JP; Martinez Vila C; Richter R; Taube E; Plett H; Braicu E; Sehouli J
Int J Gynecol Cancer; 2020 Apr; 30(4):498-503. PubMed ID: 31996397
[TBL] [Abstract][Full Text] [Related]
33. Anterior gradient protein 2 (AGR2) is an independent prognostic factor in ovarian high-grade serous carcinoma.
Darb-Esfahani S; Fritzsche F; Kristiansen G; Weichert W; Sehouli J; Braicu I; Dietel M; Denkert C
Virchows Arch; 2012 Aug; 461(2):109-16. PubMed ID: 22752467
[TBL] [Abstract][Full Text] [Related]
34. Low grade serous ovarian cancer - A rare disease with increasing therapeutic options.
Zwimpfer TA; Tal O; Geissler F; Coelho R; Rimmer N; Jacob F; Heinzelmann-Schwarz V
Cancer Treat Rev; 2023 Jan; 112():102497. PubMed ID: 36525716
[TBL] [Abstract][Full Text] [Related]
35. Low-grade serous carcinoma detected from intraoperative peritoneal washings: Cytological findings and detection of KRAS mutation.
Yamamoto E; Warigaya K; Kinoshita Y; Yamamoto A; Murata SI
Cancer Rep (Hoboken); 2022 Oct; 5(10):e1676. PubMed ID: 35801373
[TBL] [Abstract][Full Text] [Related]
36. Exploring the Clinical Impact of Predictive Biomarkers in Serous Ovarian Carcinomas.
Le Page C; Chung J; Rahimi K; Köbel M; Provencher D; Mes-Masson AM
Curr Drug Targets; 2020; 21(10):974-995. PubMed ID: 31622218
[TBL] [Abstract][Full Text] [Related]
37. [LOW GRADE OVARIAN CANCER].
Segev Y; Kaldawy A; Auslender R; Lavie O
Harefuah; 2017 Aug; 156(8):507-511. PubMed ID: 28853527
[TBL] [Abstract][Full Text] [Related]
38. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
[TBL] [Abstract][Full Text] [Related]
39. Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: an international multicentre analysis.
May T; Bernardini M; Lheureux S; Aben KKH; Bandera EV; Beckmann MW; Benitez J; Berchuck A; Bjørge L; Carney ME; Cramer DW; deFazio A; Dörk T; Eccles DM; Friedlander M; García MJ; Goode EL; Hein A; Høgdall CK; Jensen A; Johnatty S; Kennedy CJ; Kiemeney LA; Kjær SK; Kupryjańczyk J; Matsuo K; McGuire V; Modugno F; Paddock LE; Pejovic T; Phelan CM; Riggan MJ; Rodriguez-Antona C; Rothstein JH; Sieh W; Song H; Terry KL; van Altena AM; Vanderstichele A; Vergote I; Thomsen LCV; Webb PM; Wentzensen N; Wilkens LR; Ziogas A; Jiang H; Tone A;
Can J Surg; 2023; 66(3):E310-E320. PubMed ID: 37369443
[TBL] [Abstract][Full Text] [Related]
40. Mutational spectrum in clinically aggressive low-grade serous carcinoma/serous borderline tumors of the ovary-Clinical significance of BRCA2 gene variants in genomically stable tumors.
Zhang X; Devins K; Ko EM; Reyes MC; Simpkins F; Drapkin R; Schwartz LE; Yoon JY
Gynecol Oncol; 2021 Jun; 161(3):762-768. PubMed ID: 33773808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
